Briefing
Neoadjuvant botensilimab with or without balstilimab in pMMR and dMMR colon cancer: the phase 2 UNICORN trial
In this phase 2 trial, 56 patients with resectable locally advanced pMMR or dMMR colon cancer received short-course preoperative botensilimab with or without balstilimab (14 patients in each of four cohorts). Pathologic major response rates were 0% with botensilimab alone and 36% with the combination in pMMR disease, and 36% and 100% in the corresponding dMMR cohorts. The abstract reports that ctDNA clearance before surgery correlated with pathologic response and with no recurrence at data cutoff. The assay is not named in the abstract.
- Design: Evidence level 2
- Assay: Not named in the abstract
Nature MedicinePubMed 42972108DOI 10.1038/s41591-026-04710-1